Showing 2623 results
- https://www.novartis.com/news/media-releases/six-leading-scientists-receive-prestigious-novartis-prizes-immunology-16th-international-congress-immunologyThe Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and Harald von Boehmer for demonstrating that the ability of the immune system to discriminate "self" from "non-self" is…
- https://www.novartis.com/news/media-releases/alcon-launches-dailies-total1-multifocal-contact-lenses-first-and-only-water-gradient-lenses-designed-people-presbyopiaPresbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1] Dailies Total1® Multifocal contact lenses provide a seamless visual experience…
- https://www.novartis.com/news/media-releases/sandoz-biosimilar-etanercept-recommended-fda-advisory-committee-approval-treat-multiple-inflammatory-diseasesCommittee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product …
- https://www.novartis.com/stories/treatments-blood-cancers-and-serious-blood-disorders-are-advancing-rapidly-novartis-helping-lead-way
Novartis has been at the forefront of advances in how blood cancers and serious blood disorders are treated, helping patients live their best lives.
- https://www.novartis.com/news/media-releases/new-data-shows-sandoz-biosimilar-etanercept-candidate-has-equivalent-efficacy-originator-productThe EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the…
- https://www.novartis.com/news/media-releases/novartis-pkc412-midostaurin-pivotal-data-published-nejm-show-60-response-rate-advanced-systemic-mastocytosis-smIn the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…
- https://www.novartis.com/news/media-releases/largest-global-psoriasis-survey-shows-84-people-face-discrimination-and-humiliation-because-their-skinGlobal survey of over 8,300 people with moderate-to-severe psoriasis is the first to look at perceptions of clear skin[1] Nearly half (45%) have been asked if they are contagious while 55% do not…
- https://www.novartis.com/news/media-releases/novartis-adds-bispecific-antibodies-its-growing-immuno-oncology-portfolio-through-collaboration-and-licensing-agreement-xencorAgreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…
- https://www.novartis.com/news/media-releases/timely-use-novartis-entresto-could-prevent-or-postpone-over-28000-us-deaths-year-among-hfref-patients-according-expert-analysis-jama-cardiologyFindings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1] Cardiology experts…
- https://www.novartis.com/news/media-releases/novartis-expands-partnership-medicines-malaria-venture-develop-next-generation-antimalarial-treatmentNovartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- …
- 263
- › Next page